Cardiol Therapeutics Inc.CRDL.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · cardiolrx.com
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx™, targets the inflammasome pathway and is being evaluated in the pivotal Phase III MAVERIC trial for recurrent pericarditis. The company is dual-listed on the Toronto Stock Exchange and NASDAQ Capital Market and is headquartered in Canada.
Key ratios
ROA
-77.3%TTM
2025
-77.3%2024
-73.4%2023
-37.7%
ROE
-158.8%TTM
2025
-158.8%2024
-138.5%2023
-69.9%
Recent news
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
Track CRDL.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer